LANCASTER, CA, December 1, 2005 - Simulations Plus, Inc. (AMEX: SLP), a leading provider of ADMET absorption simulation and structure-to-property prediction software for pharmaceutical discovery and development, announced today that it has filed for an extension of the due date for its Form 10K-SB for the fiscal year ended August 31, 2005.
Ms. Momoko Beran, chief financial officer of Simulations Plus, said: "A number of accounting rule changes as well as schedule conflicts with our auditors and our internal staff have resulted in longer preparation time than we expected for the audit and write-up of the 10-KSB. We expect to release it not later than Friday, December 9. We'll do our best to release it sooner, but we must have the proper reviews completed before release."
Walt Woltosz, chairman and chief executive officer of Simulations Plus, added: "We will have a conference call on Tuesday, December 13, at 1:30 PM PST. This will give investors the weekend to read the 10-KSB before the call. We will also begin to provide guidance for the near future, especially for the current fiscal year, and to explain how our recent acquisitions and new product releases are combining to strengthen our offerings."
About Simulations Plus, Inc.
Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. The Company’s Words+ subsidiary produces assistive technology and communication devices for persons with disabilities. The Company also produces a line of educational simulation software under the umbrella name FutureLab™, which is based on its proprietary software technologies. Simulations Plus, Inc., is headquartered in Southern California. For more information, visit our Web sites at www.simulations-plus.com and www.words-plus.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. The actual future results of the Company could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: the ability of the Company to continue to book revenues and earnings in accordance with existing accounting standards, the ability of the Company to maintain its competitive advantage, the general economics of the disability and pharmaceutical industries, the ability of the Company to attract and maintain sufficient scientific and technical staff to sustain its R&D and customer support functions, and a sustainable market. Further information on the Company’s risk factors is contained in the Company’s quarterly and annual reports as filed with the Securities and Exchange Commission.
For further information:
Simulations Plus, Inc.
42505 10th Street West
Lancaster, CA
93534-7059 USA
www.simulations-plus.com
CONTACT: investor relations:
Contact: Renee Bouche